Wild-Type p53 Overexpression Inhibits DNA Damage Pathways and Reduces PD-L1 Expression in Prostate Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The DNA damage response (DDR) pathway is integral to tumor development and metastasis.
• PD-L1 expression influences the tumor microenvironment and is a target in cancer immunotherapy.
• The role of p53 in regulating PD-L1 and DDR in prostate cancer (PCa) requires further elucidation.

Purpose of the Study:

• To investigate the regulatory role of wild-type p53 (WT-p53) in PD-L1 expression within the context of the DDR pathway in prostate cancer.
• To analyze the correlation between p53, PD-L1, and PARP1 in clinical PCa samples.
• To evaluate the therapeutic potential of targeting the p53-DDR-PD-L1 axis in PCa.

Main Methods:

• Analysis of clinical PCa samples for protein expression of PD-L1, PD-1, p53, and PARP1.
• In vitro studies involving DU145 cell transfection to overexpress WT-p53 and PD-L1, followed by western blotting, qRT-PCR, γH2AX staining, comet assays, colony formation assays, and flow cytometry.
• In vivo studies using a mouse tumor model to assess tumor growth, protein levels, γH2AX, and DNA damage.

Main Results:

• Clinical PCa samples exhibited a significant negative correlation between p53 and PD-L1/PARP1 levels.
• WT-p53 overexpression in vitro and in vivo reduced γH2AX expression, indicating inhibition of DDR pathway activation.
• Downregulation of PARP1 and PD-L1, increased apoptosis, and suppressed PCa cell proliferation were observed upon WT-p53 overexpression.

Conclusions:

• WT-p53 activation inhibits the DDR pathway, leading to decreased PARP1 and PD-L1 expression in prostate cancer.
• These findings offer a novel mechanistic understanding and potential therapeutic strategies for PCa treatment.
• Targeting the p53-mediated regulation of DDR and PD-L1 presents a promising avenue for future PCa research and therapy.